Chikujee Therapeutics is an innovative and dynamic
company employing a unique approach to solving the
most important and complex problems associated with
targeted therapeutic delivery. By integrating the
fields of organic and polymer chemistry, polymer
physics, nanotechnology, biochemistry, and molecular
biology, Chikujee is well-positioned to develop new
polymeric biomaterials and drug carriers that will
impact the millions of people worldwide who suffer
from disease. In contrast to the use of
off-the-shelf polymers to develop "new" delivery
technologies, Chikujee looks to design and
biochemically tailor novel drug delivery vehicles to
address key problems in drug delivery. This
fundamentally different strategy has led to the
development of new Biomolecular Oligomeric Silica
hybrid (BOSH) molecules and the TSDVTM
drug
delivery platform, a versatile system that addresses
the diverse requirements for advanced target
specific drug delivery.
Research is driving the discovery, research, and
development, from Generic-to-Brand, of new
products and innovative core technologies that
improve the lives of seriously ill patients. A
key priority is to leverage and exploit the
potential for Chikujees NanoBindi TM
based Surface Engineered Nano Probes
(SENP) or Target Specific
Delivery Vehicles (TSDV)
technology, while continuing the discovery and
development of new products. Chikujee relies on
its rich research heritage with extensive
multifunctional bionanotechnology capabilities,
seasoned clinical development and regulatory
experts to accelerate clinical
proofs-of-principle leading to next-generation
technology discoveries.
